An interventional study of Extracorporeal Shock Wave Therapy and Normal Saline in Osteoarthritis (OA), sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing Hyaluronic Acid in Osteoarthritis — 2 open to participants now, 2 under way, none of them phase 3. Hyaluronic Acid · Osteoarthritis.
Among the 16 studies testing Hyaluronic Acid in Osteoarthritis, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 with no phase, and was the 16th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →2 of the 16 studies testing Hyaluronic Acid in Osteoarthritis are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 20–60
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 20+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2023.
This study's enrollment of 48 is below the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 60 across the 15 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
Chang Gung Memorial Hospital has 5 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
1 of the studies testing Hyaluronic Acid in Osteoarthritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06082531Xijing HospitalEffect of Platelet-rich Plasma (PRP) Injection on Knee Osteoarthritis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing Hyaluronic Acid in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a single group, double-blind, randomized clinical trial that enrolled 48 patients with Kellgren-Lawrence grade II to IV osteoarthritis of the knee. Patients were randomly assigned to three groups: Saline + ESWT (S+E group), High Platelet-Rich Plasma (PRP + ESWT (P+E group), and Hyaluronic Acid + ESWT (HA + ESWT (H+E group). All patients were followed for one year. Assessments included the Visual Analogue Scale (VAS), serum enzyme-linked immunosorbent assay (ELISA), knee X-ray and ultrasound examinations, and functional scores (WOMAC, KOOS, and IKDC).
This is a double-blind trial. The first year's work primarily involves patient enrollment, treatment, and evaluation. We anticipate enrollment will take one year; therefore, patients meeting the inclusion criteria will be gradually enrolled during the first year. Upon enrollment, each patient will undergo blood tests, functional assessments, X-rays, and ultrasound examinations as pre-treatment data. After treatment (depending on their assigned group), functional assessments will be performed every three months, and X-rays and ultrasound examinations will be conducted six months later. The entire treatment period for each patient is one year (6 months of treatment + 6 months of follow-up).
Extracorporeal shock wave therapy (ESWT) is a single high-amplitude sound wave generated by a high-voltage capacitor spark discharge explosion and then focused on the area we want to treat through an elliptical reflector.
Hyaluronic acid is a long-chain polymer composed of disaccharide molecules of D-glucuronic acid and N-acetylglucosamine. It is a major component of the extracellular matrix and is widely present in human body fluids and tissues, including the vitreous humor of the eye and synovial fluid of joints. During osteoarthritis, the concentration and molecular weight of endogenous hyaluronic acid decrease significantly, leading to a decline in its effectiveness in lubricating joints and dispersing intra-articular pressure . Exogenous hyaluronic acid supplementation is effective in anti-inflammatory effects, stimulating the regeneration of endogenous hyaluronic acid, and relieving pain. Current literature confirms that intra-articular injection of hyaluronic acid can be considered as a treatment option to relieve osteoarthritis when other conservative treatments are ineffective .
On the other hand, platelet-rich plasma (PRP) is an emerging treatment option for osteoarthritis of the knee (9). PRP is plasma rich in platelets that can be separated from the patient's own blood using centrifugation. Platelets are organelles in the human body that readily obtain growth factors; therefore, high-concentration platelet plasma also contains many growth factors, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor (TGF). These high concentrations of growth factors can be used to achieve tissue repair and regeneration. Previous literature has also confirmed that PRP can effectively reduce pain and improve function in patients with osteoarthritis. However, the effects of these two treatment methods on cartilage tissue improvement remain inconclusive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
phase III: Numerous bone spurs, significant narrowing of the joint cavity, and subchondral cysts visible in the subchondral bone.
phase IV: Larger and more prominent bone spurs, severe narrowing of the joint cavity, sclerosis of the subchondral bone, and even joint deformities.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each group received ESWT treatment and an injection of Saline as a placebo to prevent participants from knowing they were in the control group.
Device: Extracorporeal Shock Wave Therapy · Drug: Normal Saline
This group of patients will receive ESWT and HA injections.
Device: Extracorporeal Shock Wave Therapy · Drug: Hyaluronic Acid (HA)
This group of patients will receive ESWT and PRP injections.
Device: Extracorporeal Shock Wave Therapy · Biological: Platelet-Rich Plasma
Extracorporeal Shock Wave Therapy (ESWT) is a non-invasive, injection-free, and radiation-free treatment method commonly used to treat musculoskeletal disorders. Compared to conventional instrument-based treatments, it can reach deeper tissues. Shock waves can cause microscopic damage to injured or poorly healed tissues, promoting tissue repair, angiogenesis, and pain relief. Using a Storz Medical shockwave therapy machine at an energy of 0.25 mJ/mm², 4000 shocks were administered each time, followed by three treatments at two-week intervals.
Physiological saline solution is a mixture of sodium chloride (salt) and water, with a concentration of 0.9%, and its osmotic pressure is equal to that of human body fluids. Because sterile physiological saline solution has a simple composition and its osmotic pressure is similar to that of the human body and it has no pharmacological activity, it is often used as a sham treatment control group.
Hyaluronic acid (also known as hyaluronic acid) is a biological polysaccharide with high water absorption and viscoelasticity. It is a component of the articular cartilage matrix and one of the main components of joint lubricating fluid. Hyaluronic acid in the joint cavity can help joints move smoothly, cushion impacts, and reduce wear and tear between articular cartilage.
PRP therapy mainly involves drawing the patient's own blood, centrifuging it at high speed through a special extraction tube to separate platelets, and then injecting the concentrated platelets into the joint cavity. Utilizing the repair and regeneration capabilities of the growth factors abundant in the platelet vesicles, it repairs the worn-out meniscus cartilage, promotes tissue regeneration, and relieves the pain of degenerative knee osteoarthritis.
VAS(Visual Analogue Scale)
VAS(Visual Analogue Scale):Ask the patient to mark the degree of their pain on a 10 cm line, from "no pain" on the far left to "unbearable pain" on the far right. The "Numerical Rating Scale" uses a numerical concept of 0-10 points to express the degree of pain, from no pain (0 points) to very painful (10 points).
Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.
WOMAC(Western Ontario and McMaster Universities Arthritis Index)
WOMAC is a standardized questionnaire specifically designed to assess the symptoms and functional status of osteoarthritis (degenerative joint disease) of the knee and hip. WOMAC contains 24 items, divided into three categories. Pain (5 items): Assess the degree of pain when walking, climbing stairs, lying down, sitting, or standing. Score range: 0 to 20. Stiffness (2 items): Assess the feeling of stiffness in the joints upon waking in the morning and after resting during the day. Score range: 0 to 8. Physical Function (17 items): Assess the difficulty of performing daily activities such as climbing stairs, getting up, bending over, walking, putting on socks, and doing housework. Score range: 0 to 68.The Likert scale was used for scoring:0 for none, 1 for mild, 2 for moderate, 3 for severe, and 4 for very severe. Total score: The sum of the three scores ranges from 0 to 96. A higher score indicates more severe arthritis symptoms and greater functional impairment.
Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.
KOOS scale (Knee Injury and Osteoarthritis Outcome Score)
The KOOS scaleis a standardized questionnaire used to assess the subjective symptoms and quality of life of patients with knee injuries and osteoarthritis. KOOS contains 42 items, independently assessing the following five subscales: 1. Pain: Assessing the frequency and severity of knee pain. 2. Other symptoms: Including swelling, clicking, limited extension or flexion, etc. 3. Daily Living Functions : Ease of performing everyday actions such as going down stairs, sitting down, and putting on socks. 4. Sport/Rec: Performance in activities such as running, jumping, kneeling, or squatting.5. Quality of Life : The psychological impact and distress caused by knee condition on daily life. Scoring Method: Each item is scored on a Likert scale from 0 to 4. Score Range: Each of the five categories is calculated independently and converted to a percentage scale from 0 to 100. Score Meaning: 0 represents the worst knee condition, extremely severe; 100 represents no symptoms and excellent knee
Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.
IKDC (International Knee Documentation Committee Subjective Knee Form)
IKDC is suitable for patients with various knee joint conditions (such as ligament injuries, meniscus tears, cartilage problems, or osteoarthritis), and is particularly commonly used for sports injuries and post-operative follow-up. It covers three main categories: symptoms (pain, stiffness, swelling, locking, or weakness. Assess three core symptom categories: assess frequency and severity of pain, stiffness, swelling, joint locking, or knee displacement. Assess sports and activities: assess limitations in daily activities (such as climbing stairs, standing up from a chair, squatting) and during movement or jumping. Assess current overall knee function: the patient's rating of their current knee condition compared to before the injury. Scoring and Interpretation: Score range: 0 to 100. Meaning: Higher scores indicate better function and fewer symptoms; 100 points indicates no symptoms and no limitations in daily life or sports.
Time frame: Functional assessments were performed at months 0, 3, 6, 9, and 12 of the treatment course.
Enzyme-Linked Immunosorbent Assay
The serum levels of inflammatory factors cytokine IL-6, metabolic inflammatory factor Leptin, cartilage factor COMP (cartilage oligometric protein), osteoinhibitory protein DKK-1 (Dickkopf-1), and cartilage-degrading enzyme MMP-3 (Matrix Metalloproteinase-3) were analyzed.
Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.
Ultrasound Assessment: Joint Effusion
Measurement of joint effusion in the knee joint using ultrasound examination.Unit of Measure:millimeter (mm)
Time frame: Functional assessments are performed at months 0, 6, and 12 of treatment.
Ultrasound Assessment: Medial Meniscus (MM) Extrusions Width at Full Extension
Measurement of medial meniscus extrusion width at full extension using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.
Ultrasound Assessment: Medial Meniscus (MM) Extrusion Width at Standing Weight-Bearing
Measurement of medial meniscus extrusion width during standing weight-bearing using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.
Ultrasound Assessment: Medial Collateral Ligament (MCL) Thickness at Full Extension
Measurement of medial collateral ligament thickness at full extension using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.
Ultrasound Assessment: Medial Collateral Ligament (MCL) Thickness at Standing Weight-Bearing
Measurement of medial collateral ligament thickness during standing weight-bearing using ultrasound examination.Unit of Measure: millimeter(mm)
Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.
Ultrasound Assessment: Doppler Signal at Medial Meniscus (MM) Body
Assessment of vascularization and inflammation via Doppler ultrasound signal at the medial meniscus body.Unit of Measure: ( Semi-quantitative scale, 0-3)
Time frame: Functional assessments were performed at months 0, 6, and 12 of the treatment course.
Plan to share: No — Patient privacy and Institutional Review Board regulations
No publications or documents are linked to this record.
Ran from Aug 2023 to primary completion in Jun 2025, 22 months.
Of 576 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's 22 months is below that.
Counting every sponsor, half of 711 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hyaluronic Acid · Platelet rich plasma
Chang Gung Memorial Hospital →